C4X Discovery

News

Introducing the Sunday Times Tech 100: Life sciences part 3

In our third and final report on the 2026 Sunday Times Tech 100, we focus on the remaining crop of life sciences companies in the hardware category.

News

Redx joins C4X in delisting from AIM due to liquidity issues

UK company Redx Pharma has decided it would be better off in private hands than publicly listed on the Alternative Investment Market (AIM), and has started the process of

Views & Analysis

Clive Dix: Rebuilding UK biotech

UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce.

Introducing the Sunday Times Tech 100: Life sciences part 3

Redx joins C4X in delisting from AIM due to liquidity issues

Clive Dix: Rebuilding UK biotech

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Editor's Picks